In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 101 to 125 of 401

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Diabetic retinopathy - ruboxistaurin [ID382]	Technology appraisal guidance	TBC
Digital platforms to support cardiac rehabilitation: early value assessment	Health technology evaluation	18 November 2025
Digital platforms to support rehabilitation before and after hip or knee replacement surgery	Health technology evaluation	TBC
Digital self-help for eating disorders: early value assessment	Health technology evaluation	13 November 2025
Digital technologies delivering CBT for insomnia and insomnia symptoms (provisional title)	Health technology evaluation	TBC
Digital technologies for managing mild to moderate hip or knee osteoarthritis: early-value assessment	Health technology evaluation	16 January 2026
Digital technologies to support asthma self-management: early value assessment	Health technology evaluation	17 April 2026
Digital technologies to support smoking cessation in secondary care patients: early value assessment	Health technology evaluation	TBC
Domestic violence and abuse: multi-agency working	NICE guideline	TBC
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]	Technology appraisal guidance	TBC
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]	Technology appraisal guidance	18 June 2026
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]	Technology appraisal guidance	TBC
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [ID6415]	Technology appraisal guidance	10 September 2025
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]	Highly specialised technology	5 June 2026
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]	Technology appraisal guidance	TBC
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID6235	Technology appraisal guidance	TBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]	Technology appraisal guidance	TBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]	Technology appraisal guidance	29 October 2025
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]	Technology appraisal guidance	TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]	NICE guideline	TBC
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]	Technology appraisal guidance	TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]	Technology appraisal guidance	TBC
Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]	Technology appraisal guidance	4 February 2026
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317	Technology appraisal guidance	TBC
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]	Technology appraisal guidance	TBC

Results per page

10
25
50
All